Nathan Fowler

Nathan Fowler

UNVERIFIED PROFILE

Are you Nathan Fowler?   Register this Author

Register author
Nathan Fowler

Nathan Fowler

Publications by authors named "Nathan Fowler"

Are you Nathan Fowler?   Register this Author

100Publications

3481Reads

11Profile Views

CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.

Leuk Lymphoma 2019 Sep 18:1-9. Epub 2019 Sep 18.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1663418DOI Listing
September 2019

Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes.

Clin Lymphoma Myeloma Leuk 2019 Jun 26;19(6):381-389. Epub 2019 Feb 26.

Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.02.011DOI Listing
June 2019

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.

Leuk Lymphoma 2019 Jun 24:1-8. Epub 2019 Jun 24.

a Department of Radiation Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1627535DOI Listing
June 2019

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Ann Hematol 2019 May 8;98(5):1169-1176. Epub 2019 Jan 8.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3571-7
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3571-7DOI Listing
May 2019

Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data.

Cancer Causes Control 2019 May 19;30(5):477-488. Epub 2019 Mar 19.

Department of Radiology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-019-01144-8DOI Listing
May 2019

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

N Engl J Med 2019 05;380(22):2095-2103

From the Departments of Leukemia (N.J., M. Keating, P.T., A.F., J.B., G.B., K.T., Z.E., T.K., M. Konopleva, Y.A., M.Y., C.D., P.B., M.O., N.P., E.J., K. Sasaki, K. Sondermann, N.C., C.W., A.A., H.K., W.W.), Lymphoma and Myeloma (N.F.), Hematopathology (R.K.-S., K.P., J.J.), Diagnostic Radiology (N.G.), Biostatistics (X.W.), and Experimental Therapeutics (W.P., V.G.), University of Texas M.D. Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1900574DOI Listing
May 2019

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.

Br J Haematol 2019 Apr 5;185(2):334-338. Epub 2018 Jul 5.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15444DOI Listing
April 2019

Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides.

Leuk Lymphoma 2019 Apr 10;60(4):1079-1082. Epub 2018 Oct 10.

a MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1516879DOI Listing
April 2019

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

J Clin Oncol 2018 08 27;36(22):2259-2266. Epub 2018 Mar 27.

Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Neil Chua, University of Alberta, Edmonton, Alberta; Greg Dueck, British Columbia Cancer Agency, Kelowna; Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Jiri Mayer, University Hospital and Masaryk University, Brno; Marek Trněný, Charles University General Hospital, Prague, Czech Republic; Kamal Bouabdallah, Centre Hospitalier Universitaire Haut-Leveque, Bordeaux; Vincent Delwail, Centre Hospitalier Universitaire de Poitiers, Poitiers; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France; Nathan Fowler, University of Texas, Houston, TX; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA; John G. Gribben, Queen Mary University of London, London; Anne Lennard, Newcastle University, Newcastle upon Tyne, United Kingdom; Pieternella J. Lugtenburg, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and Günter Fingerle-Rowson, Federico Mattiello, and Andrea Knapp, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.3656
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.3656DOI Listing
August 2018

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

J Clin Oncol 2018 08 31;36(23):2405-2412. Epub 2018 May 31.

Ajay K. Gopal, The University of Washington; Ajay K. Gopal, Fred Hutchinson Cancer Research Center, Seattle, WA; Stephen J. Schuster, Abramson Cancer Center of the University of Pennsylvania, Philadelphia; Jing-Zhou Hou, University of Pittsburgh Medical Center; Jing-Zhou Hou, University of Pittsburgh Cancer Institute, Pittsburgh; Rajendra N. Damle, Michael Schaffer, and Sriram Balasubramanian, Janssen Research & Development, Spring House, PA; Nathan H. Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX; Judith Trotman, Concord Hospital, University of Sydney, Sydney, New South Wales; Andrew Spencer, Alfred Hospital-Monash University, Melbourne, Victoria; James Morton, Haematology and Oncology Clinics of Australia, Milton, Queensland, Australia; Georg Hess, Johannes Gutenberg-University, Mainz, Germany; Abdulraheem Yacoub, Kansas University Medical Center, Kansas City, KS; Michael Lill, Cedars-Sinai Medical Center, Los Angeles, CA; Peter Martin, Weill Cornell Medical College, Cornell University, New York, NY; Umberto Vitolo, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; John Radford, University of Manchester; John Radford, Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Dolores Caballero, Hospital Clínico Universitario, Salamanca, Spain; Sanjay Deshpande, Gary J. Gartenberg, and Shean-Sheng Wang, Janssen Research & Development, Raritan, NJ; Jessica Vermeulen, Janssen Research & Development, Leiden, the Netherlands; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; and Gilles Salles, Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite cedex, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8853DOI Listing
August 2018

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.

Ophthalmic Plast Reconstr Surg 2018 Aug 17. Epub 2018 Aug 17.

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001215DOI Listing
August 2018

Novel agents for relapsed and refractory follicular lymphoma.

Best Pract Res Clin Haematol 2018 03 16;31(1):41-48. Epub 2017 Nov 16.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2017.11.003DOI Listing
March 2018

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Clin Lymphoma Myeloma Leuk 2018 01 14;18(1):e103-e108. Epub 2017 Nov 14.

Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.11.001DOI Listing
January 2018

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Br J Haematol 2017 12 9;179(5):851-854. Epub 2016 Aug 9.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063086PMC
December 2017

Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.

Am J Surg Pathol 2017 Oct;41(10):1309-1321

*Department of Oncology, The First Affiliated Hospital Zhengzhou University, Zhengzhou, China Departments of †Hematopathology ‡Radiation Oncology §Bioinformatics and Computational Biology ∥Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center #Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX ¶Department of Pathology, Harvard University Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000923DOI Listing
October 2017

Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma.

Ophthalmic Plast Reconstr Surg 2017 Sep/Oct;33(5):355-360

*Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, †Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, ‡Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, Galveston, Texas, U.S.A.; §Narayana Nethralaya, Narayana Health City, Bangalore, India; ‖Department of Lymphoma and Myeloma, ¶Department of Radiation Oncology, and #Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000000789DOI Listing
September 2017

The landscape of new drugs in lymphoma.

Nat Rev Clin Oncol 2017 Jun 29;14(6):335-346. Epub 2016 Dec 29.

UNMC Oncology/Haematology Division, 987680 Nebraska Medical Center, Omaha, Nebraska 681980-7680, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611863PMC
June 2017

Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease.

Am J Hematol 2017 May 7;92(5):478-479. Epub 2016 Dec 7.

Department of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24603DOI Listing
May 2017

Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.

Clin J Oncol Nurs 2017 04;21(2 Suppl):53-59

University of Texas MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/17.CJON.S2.53-59DOI Listing
April 2017

Recommendations for Clinical Trial Development in Follicular Lymphoma.

J Natl Cancer Inst 2017 03 31;109(3). Epub 2016 Dec 31.

Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059137PMC
March 2017

Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary.

Authors:
Nathan H Fowler

Clin Adv Hematol Oncol 2017 Mar;15 Suppl 3(3):21-23

Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
March 2017

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

J Clin Oncol 2017 Feb 28;35(5):552-560. Epub 2016 Dec 28.

Qian Shi and Daniel J. Sargent, Mayo Clinic, Rochester; Bruce A. Peterson, University of Minnesota, Minneapolis, MN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Wolfgang Hiddemann and Eva Hoster, Ludwig-Maximilians University Hospital, Munich; Michael Herold, HELIOS Kliniken, Erfurt, Germany; Robert Marcus, Addenbrooke's Hospital, Cambridge, United Kingdom; Anton Hagenbeek, Academic Medical Center, Amsterdam, the Netherlands; Eva Kimby, Karolinska Institutet, Stockholm, Sweden; Howard Hochster, Yale Cancer Center, New Haven, CT; Umberto Vitolo, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin; Marco Ladetto, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Emmanuel Gyan, University Hospital, Tours; Franck Morschhauser, Service Université de Lille 2, Lille; Gilles Salles, Université Claude Bernard, Pierre Bénite, France; Michele Ghielmini and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona; Michele Ghielmini and Emanuele Zucca, Swiss Group for Clinical Cancer Research, Bern; Tina Nielsen, F. Hoffmann-La Roche, Basel; Sabine De Bedout, Celgene, Boudry, Switzerland; Tommy Fu, Celgene, Summit, NJ; Nancy Valente, Genentech, South San Francisco, CA; and Nathan H. Fowler, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8651DOI Listing
February 2017

The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia.

Leuk Lymphoma 2016 16;57(6):1487-90. Epub 2015 Nov 16.

a Department of Infectious Diseases , Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1099649DOI Listing
January 2017

Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?

Authors:
Nathan Fowler

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):277-283

Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142520PMC
December 2016

Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.

Leuk Lymphoma 2016 08 13;57(8):1974-6. Epub 2016 Jan 13.

a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1124993DOI Listing
August 2016

Idelalisib in the management of lymphoma.

Blood 2016 07 1;128(3):331-6. Epub 2016 Jun 1.

The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-02-702761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161010PMC
July 2016

Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience.

Am J Clin Oncol 2016 Apr;39(2):109-13

Departments of *Radiation Oncology †Hematopathology ‡Ophthalmology ∥Lymphoma Medical Oncology, The University of Texas MD Anderson Cancer Center §Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000028DOI Listing
April 2016

Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.

Neuro Oncol 2016 Apr 20;18(4):575-81. Epub 2015 Oct 20.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas (C.Y.C., D.C., N.H.F.); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.M., C.C.P., B.S.D.); Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, Texas (D.S.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799685PMC
April 2016

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Br J Haematol 2015 Nov 27;171(4):463-70. Epub 2015 Jul 27.

Department of Lymphoma/Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278973PMC
November 2015

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

Haematologica 2015 Nov 6;100(11):e454-7. Epub 2015 Aug 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.131144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825296PMC
November 2015

Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease.

Clin Lymphoma Myeloma Leuk 2015 Nov 5;15(11):664-670.e2. Epub 2015 Aug 5.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.07.633DOI Listing
November 2015

Chemotherapy-Free Treatment of Follicular Lymphoma: We Have the Ingredients, Now for Some Recipes.

Oncology (Williston Park) 2015 Oct;29(10):769, 772

View Article

Download full-text PDF

Source
October 2015

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

J Clin Oncol 2015 Sep 20;33(25):2803-11. Epub 2015 Jul 20.

John G. Gribben, Barts Cancer Institute, London, United Kingdom; Nathan Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX; and Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Unité Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320950PMC
September 2015

Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.

Curr Opin Oncol 2015 Sep;27(5):384-91

Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000212DOI Listing
September 2015

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.

Haematologica 2015 Jul 27;100(7):e272-4. Epub 2015 Mar 27.

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.126557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486240PMC
July 2015

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.

Ann Hematol 2015 Apr 30;94(4):633-41. Epub 2015 Jan 30.

Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2269-8DOI Listing
April 2015

Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population.

J Natl Compr Canc Netw 2015 Jan;13(1):41-50

From the Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center; The University of Texas School of Public Health; and the Departments of Gastroenterology, Hepatology and Nutrition, Gastrointestinal Medical Oncology, and Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0007DOI Listing
January 2015

R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.

Authors:
Nathan H Fowler

Clin Adv Hematol Oncol 2014 Sep;12(9):608-10

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
September 2014

Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease.

J Neurol Sci 2014 Aug 15;343(1-2):46-50. Epub 2014 May 15.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, R6.1617, Houston, TX 77030, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2014.05.015DOI Listing
August 2014

Indolent and mantle cell NHL: the future is BRIGHT.

Authors:
Nathan Fowler

Blood 2014 May;123(19):2905-6

MD ANDERSON CANCER CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-03-562124DOI Listing
May 2014

Integrating emerging treatment options in mantle cell lymphoma.

Clin Adv Hematol Oncol 2013 Dec;11(12 Suppl 19):1-15

UW Carbone Cancer Center, Madison, Wisconsin.

View Article

Download full-text PDF

Source
December 2013

Unmet needs in the treatment of mantle cell lymphoma.

Clin Adv Hematol Oncol 2013 Nov;11(11 Suppl 18):1-19

Northwestern University Feinberg School of Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
November 2013